420 related articles for article (PubMed ID: 4039568)
41. In vitro inhibition of renal sodium-potassium ATPase activity by progesterone.
Lijnen P; Groeseneken D; Lommelen L; M'Buyamba-Kabangu JR; Amery A
Methods Find Exp Clin Pharmacol; 1985 Jul; 7(7):347-9. PubMed ID: 2997558
[TBL] [Abstract][Full Text] [Related]
42. Inhibitory effects of the novel anti-aldosterone compound mespirenone on adrenocortical steroidogenesis in vitro.
Weindel K; Lewicka S; Vecsei P
Arzneimittelforschung; 1991 Sep; 41(9):946-9. PubMed ID: 1796922
[TBL] [Abstract][Full Text] [Related]
43. Experimental studies on the endocrine side effects of new aldosterone antagonists.
Nishino Y; Schröder H; el Etreby MF
Arzneimittelforschung; 1988 Dec; 38(12):1800-5. PubMed ID: 3245852
[TBL] [Abstract][Full Text] [Related]
44. Effects of mineralocorticoids on Na+ and K+ excretion in the adrenalectomized rat.
Horisberger JD; Diezi J
Am J Physiol; 1983 Jul; 245(1):F89-99. PubMed ID: 6869541
[TBL] [Abstract][Full Text] [Related]
45. Independence of antimineralocorticoid and catatoxic effects of various steroids.
Solymoss B; Krajny M; Varga S
J Pharm Sci; 1970 May; 59(5):712-4. PubMed ID: 4392820
[TBL] [Abstract][Full Text] [Related]
46. Extrarenal effects of aldosterone and antimineralocorticoid compounds.
Moura AM; Angeli M; Worcel M
Kidney Int Suppl; 1988 Oct; 26():S8-11. PubMed ID: 2848978
[No Abstract] [Full Text] [Related]
47. Effect of spironolactone treatment on the renin-aldosterone system during pregnancy.
Lammintausta R; Erkkola R
Int J Clin Pharmacol Biopharm; 1979 Jul; 17(7):294-8. PubMed ID: 489194
[TBL] [Abstract][Full Text] [Related]
48. Effects of acute mineralocorticoid and glucocorticoid receptor blockade on the excretion of an acute potassium load in healthy humans.
van Buren M; Boer P; Koomans HA
J Clin Endocrinol Metab; 1993 Oct; 77(4):902-9. PubMed ID: 8408463
[TBL] [Abstract][Full Text] [Related]
49. Comparison of prorenoate potassium and spironolactone after repeated doses and steady state plasma levels of active metabolites.
McInnes GT; Shelton JR; Harrison IR; Perkins RM; Palmer RF
Br J Clin Pharmacol; 1982 Feb; 13(2):187-94. PubMed ID: 7059416
[TBL] [Abstract][Full Text] [Related]
50. Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18beta-glucuronidation: a potential drug interaction.
Knights KM; Bowalgaha K; Miners JO
Drug Metab Dispos; 2010 Jul; 38(7):1011-4. PubMed ID: 20304966
[TBL] [Abstract][Full Text] [Related]
51. Spironolactone and potassium canrenoate in normal man.
Ramsay L; Shelton J; Harrison I; Tidd M; Asbury M
Clin Pharmacol Ther; 1976 Aug; 20(2):167-77. PubMed ID: 780038
[TBL] [Abstract][Full Text] [Related]
52. 19-Nor progesterone is a mineralocorticoid agonist.
Funder JW; Adam WR
Endocrinology; 1981 Jul; 109(1):313-5. PubMed ID: 6263590
[TBL] [Abstract][Full Text] [Related]
53. A preclinical pharmacokinetic and pharmacodynamic approach to determine a dose of spironolactone for treatment of congestive heart failure in dog.
Guyonnet J; Elliott J; Kaltsatos V
J Vet Pharmacol Ther; 2010 Jun; 33(3):260-7. PubMed ID: 20557443
[TBL] [Abstract][Full Text] [Related]
54. Induction of flavokinase (EC 2.7.1.26) by aldosterone in the rat kidney.
Trachewsky D; Oakes ML; Morris DJ
Endocrinology; 1985 Mar; 116(3):879-88. PubMed ID: 2982577
[TBL] [Abstract][Full Text] [Related]
55. Antinatriuretic and kaliuretic activities of the reduced derivatives of aldosterone.
Kenyon CJ; Brem AS; McDermott MJ; Deconti GA; Latif SA; Morris DJ
Endocrinology; 1983 May; 112(5):1852-6. PubMed ID: 6403339
[TBL] [Abstract][Full Text] [Related]
56. Mineralocorticoid activity of 19-hydroxyaldosterone, 19-nor-aldosterone, and 3 beta-hydroxy-delta 5-aldosterone: relative potencies measured in two bioassay systems.
Morris DJ; Brem AS; Saccoccio NA; Pacholski M; Harnik M
Endocrinology; 1986 Jun; 118(6):2505-9. PubMed ID: 3084221
[TBL] [Abstract][Full Text] [Related]
57. Characterization of the novel progestin gestodene by receptor binding studies and transactivation assays.
Fuhrmann U; Slater EP; Fritzemeier KH
Contraception; 1995 Jan; 51(1):45-52. PubMed ID: 7750284
[TBL] [Abstract][Full Text] [Related]
58. Glucocorticoid inhibition of mineralocorticoid action in the rat.
Kenyon CJ; Saccoccio NA; Morris DJ
Clin Sci (Lond); 1984 Sep; 67(3):329-35. PubMed ID: 6380888
[TBL] [Abstract][Full Text] [Related]
59. Aldosterone antagonists. 1. Synthesis and activities of 6 beta,7 beta:15 beta,16 beta-dimethylene steroidal spirolactones.
Nickisch K; Bittler D; Casals-Stenzel J; Laurent H; Nickolson R; Nishino Y; Petzoldt K; Wiechert R
J Med Chem; 1985 May; 28(5):546-50. PubMed ID: 3989815
[TBL] [Abstract][Full Text] [Related]
60. Difference of in vivo and in vitro antimineralocorticoid potency of progesterone.
Quinkler M; Diederich S
Endocr Res; 2002 Nov; 28(4):465-70. PubMed ID: 12530650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
